Navigation Links
Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI

Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on incidence of mortality at 30 days is the attribute that most influences surveyed cardiologists' prescribing decisions in non-ST elevation myocardial infarction (NSTEMI). Data and the opinions of interviewed thought leaders indicate that current and emerging drugs, including Eli Lilly/Daiichi Sankyo's Efient, have no advantage in this attribute over The Medicines Company's Angiomax, the market sales leading agent.

The new report entitled NSTEMI: Finding the Balance between Efficacy and Safety finds that a drug that reduces mortality more than Angiomax at 30 days with significantly lower rates of bleeding would earn a 50 percent patient share in the United States and a 60 percent patient share in Europe, according to surveyed U.S. and European cardiologists. Angiomax, which was Decision Resources' proprietary clinical gold standard in 2008 for NSTEMI, will remain the clinical gold standard therapy and the market share leader through 2017, due to its efficacy and safety

The report finds that although some therapies in development for NSTEMI hold promise, most have either efficacy or safety and tolerability features that surveyed cardiologists rated inferior when compared with Angiomax. New agents in the market include Efient, which was approved by the European Medicines Agency in February 2009 for treatment of NSTEMI in the European Union.

"Angiomax has the most robust clinical data of drugs in its class for its use in NSTEMI and benefits from an immediate onset of action, which has driven physician usage and has enabled it to dominate the NSTEMI market," said Decision Resources Analyst Amir Mobasheri. "However, Efient and other emerging drugs such as AstraZeneca's ticagrelor, The Medicines Company's cangrelor and GlaxoSmithKline's Arixtra are not expected to achieve a market share as high as that of Angiomax, largely owing to safety or efficacy concerns."

About the Report

NSTEMI: Finding the Balance between Efficacy and Safety is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563        

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
2. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
3. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
4. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
5. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
6. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
Post Your Comments:
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
(Date:11/24/2015)... , UAE, November 24, 2015   ... and dietician deliver s advice and ...   More than 50% of ... to keep themselves healthy according to the DHA   femMED ... in the UAE    Dubai residents are not ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... collaboration with U2 lead singer and activist Bono as part ... prevent vision impairment and blindness in more than 5 million ... Revo will donate $10 from the sale of every ... up to a total of $10 million to the "Buy ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):